Oxford, United Kingdom

Deborah Gill

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 2.8

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2014-2022

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Deborah Gill: Innovator in Gene Therapy

Introduction

Deborah Gill is a prominent inventor based in Oxford, GB. She has made significant contributions to the field of gene therapy, particularly through her innovative patents. With a total of 3 patents, her work focuses on advancing medical treatments for various diseases.

Latest Patents

One of her latest patents is a nucleic acid construct that provides a promoter for high-level and sustained expression. This construct can be utilized for gene expression of selected sequences. Specifically, it includes a hCEF1 promoter operably linked to a sequence for expression, which comprises a human CMV enhancer linked to a human EFI a promoter. Another notable patent involves lentiviral vectors, which are gene transfer vectors pseudotyped with hemagglutinin-neuraminidase and fusion proteins from a respiratory paramyxovirus. These vectors are designed for gene therapy, particularly targeting respiratory tract diseases such as Cystic Fibrosis.

Career Highlights

Throughout her career, Deborah has worked with notable companies, including Ip2ipo Innovations Limited and Isis Innovation Limited. Her expertise in gene therapy has positioned her as a key figure in the development of innovative medical solutions.

Collaborations

Deborah has collaborated with esteemed colleagues such as Stephen Hyde and Eric Walter Frederick Wolfgang Alton. These partnerships have further enhanced her research and contributions to the field.

Conclusion

Deborah Gill's work in gene therapy exemplifies her commitment to innovation and improving healthcare outcomes. Her patents reflect her dedication to advancing medical science and providing solutions for challenging diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…